See the DrugPatentWatch profile for Repatha
What is Repatha (evolocumab), and what is it used for?
Repatha is a brand-name injectable medicine (evolocumab) that lowers low-density lipoprotein cholesterol (LDL-C) by blocking PCSK9, a protein that affects how the liver clears LDL from the blood.[1]
It is used for adults with certain inherited or high-risk conditions, including people who need additional LDL lowering despite lifestyle changes and/or other lipid-lowering therapies.[1]
How does Repatha work?
Repatha is a PCSK9 inhibitor. By blocking PCSK9, it increases the liver’s ability to remove LDL cholesterol from the bloodstream, which lowers LDL-C levels.[1]
How is Repatha taken (dose and schedule)?
Repatha is given by subcutaneous injection. Common schedules include every 2 weeks or once monthly (depending on the specific regimen prescribed).[1]
What results should patients expect?
The main expected effect is a substantial reduction in LDL-C. The degree of LDL lowering and the time to see changes depend on the individual and the broader treatment plan, but the drug is specifically designed to reduce LDL-C through its PCSK9 mechanism.[1]
What side effects are patients asking about?
Like other medicines, Repatha can cause side effects. Commonly discussed categories include injection-site reactions and other effects related to immune or biologic therapy, though the exact risk profile depends on the patient’s situation and concurrent medications.[1]
Who might not be a good fit for Repatha?
Repatha is for people who meet specific clinical criteria for PCSK9 inhibition and LDL-C lowering. A clinician also considers overall cardiovascular risk, other lipid-lowering treatments already in use, and patient history when deciding whether Repatha is appropriate.[1]
Is Repatha a generic, and does it have patent/exclusivity coverage?
Repatha is not a traditional small-molecule generic; it is a biologic. Coverage and availability depend on patent and exclusivity status, which can be tracked through patent monitoring resources such as DrugPatentWatch.com.[2]
What’s the difference between Repatha and similar PCSK9 medicines?
Repatha is one PCSK9 inhibitor; another widely used PCSK9 option is Praluent (alirocumab). The key practical difference is the specific biologic drug (and dosing options), while both target PCSK9 to lower LDL-C.[1]
Sources
- https://www.repatha.com/
- https://www.drugpatentwatch.com/